An RCT was conducted to ascertain whether, compared to control management, topical application of a novel fibrin sealant (Evicel, J&J) in patients undergoing primary TKA reduces peri-operative blood loss. Sixty-two patients were randomized to receive topical application of Evicel (N. = 31) or not (N. = 31). The mean total blood loss was 1.9. L(±. 0.7) in the control group and 1.8. L(±. 0.5) in the treatment group (P= 0.4). The transfusion rate was 32.3% in the control group and 25.8% in the treatment group (P= 0.5). The transfusion rate decreased linearly with increasing preoperative Hb levels in the treatment group (P= 0.005). The results of this study suggest that topical application of this novel fibrin sealant doesn't reduce perioperative blood loss and the need for allogeneic blood transfusion.
Is the newest fibrin sealant an effective strategy to reduce blood loss after total knee arthroplasty? : a randomized controlled study / F. Randelli, R. D'Anchise, V. Ragone, L. Serrao, P. Cabitza, P. Randelli. - In: THE JOURNAL OF ARTHROPLASTY. - ISSN 0883-5403. - 29:8(2014 Aug), pp. 1516-1520. [10.1016/j.arth.2014.02.024]
Is the newest fibrin sealant an effective strategy to reduce blood loss after total knee arthroplasty? : a randomized controlled study
P. CabitzaPenultimo
;P. RandelliUltimo
2014
Abstract
An RCT was conducted to ascertain whether, compared to control management, topical application of a novel fibrin sealant (Evicel, J&J) in patients undergoing primary TKA reduces peri-operative blood loss. Sixty-two patients were randomized to receive topical application of Evicel (N. = 31) or not (N. = 31). The mean total blood loss was 1.9. L(±. 0.7) in the control group and 1.8. L(±. 0.5) in the treatment group (P= 0.4). The transfusion rate was 32.3% in the control group and 25.8% in the treatment group (P= 0.5). The transfusion rate decreased linearly with increasing preoperative Hb levels in the treatment group (P= 0.005). The results of this study suggest that topical application of this novel fibrin sealant doesn't reduce perioperative blood loss and the need for allogeneic blood transfusion.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S0883540314001168-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
296.57 kB
Formato
Adobe PDF
|
296.57 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.